Chelsea Counsel Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Chelsea Counsel Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67K	Hold	150	–	–	0.03%	127
2025 Q4	$68K	Hold	150	–	–	0.03%	122
2025 Q3	$58.7K	Hold	150	–	–	0.03%	130
2025 Q2	$66.8K	Hold	150	–	–	0.03%	127
2025 Q1	$72.7K	Hold	150	–	–	0.04%	121
2024 Q4	$60.4K	Hold	150	–	–	0.03%	125
2024 Q3	$69.8K	Hold	150	–	–	0.03%	125
2024 Q2	$70.3K	Buy	+150	New	+$65.1K	0.04%	118
2015 Q2	–	Sell	-2,300	Closed	-$271K	–	167
2015 Q1	$271K	Hold	2,300	–	–	0.06%	115
2014 Q4	$273K	Buy	+2,300	New	+$259K	0.06%	113

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Chelsea Counsel Company's VRTX Position: Q1 2026 in Review

Chelsea Counsel Company held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 150 shares worth $67K. The position accounts for 0.03% of the portfolio, ranked #127.

Chelsea Counsel Company first reported a position in VRTX in Q4 2014 and has held it in 10 quarters since. The position peaked at $273K in Q4 2014. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Chelsea Counsel Company held 150 shares of Vertex Pharmaceuticals worth $67K as of Q1 2026.
Chelsea Counsel Company left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.03% of Chelsea Counsel Company's portfolio in Q1 2026, its #127 holding.
Chelsea Counsel Company first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
Chelsea Counsel Company's Vertex Pharmaceuticals position peaked at $273K in Q4 2014.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.